cho host cell line development strategies ssi (Pfizer Inc)
90
Structured Review
Pfizer Inc
cho host cell line development strategies ssi
Cho Host Cell Line Development Strategies Ssi, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cho+host+cell+line+development+strategies+ssi/cho+host+cell+line+development+strategies+ssi/pm28480558-85-5-4
Average 90 stars, based on 1 article reviews
Cho Host Cell Line Development Strategies Ssi, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cho+host+cell+line+development+strategies+ssi/cho+host+cell+line+development+strategies+ssi/pm28480558-85-5-4
Average 90 stars, based on 1 article reviews
cho host cell line development strategies ssi - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Generated:Article Title: Strategic deployment of CHO expression platforms to deliver Pfizer's Monoclonal Antibody Portfolio. Article Snippet: Development of stable cell lines for expression of large molecule therapeutics represents a significant portion of the time and effort required to advance a molecule to enabling regulatory toxicology studies and clinical evaluation.. Our development strategy employs two different approaches for cell line development based on the needs of a particular project – a random integration approach for projects where high level expression is critical, and a site-specific integration approach for projects in which speed and reduced employee time spend is a necessity.. Here we describe both our random integration and site-specific integration platforms and their applications in support of monoclonal antibody development and production. Clone Assay:Article Title: Strategic deployment of CHO expression platforms to deliver Pfizer's Monoclonal Antibody Portfolio. Article Snippet: Development of stable cell lines for expression of large molecule therapeutics represents a significant portion of the time and effort required to advance a molecule to enabling regulatory toxicology studies and clinical evaluation.. Our development strategy employs two different approaches for cell line development based on the needs of a particular project – a random integration approach for projects where high level expression is critical, and a site-specific integration approach for projects in which speed and reduced employee time spend is a necessity.. Here we describe both our random integration and site-specific integration platforms and their applications in support of monoclonal antibody development and production. |